Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.

Johanna SchneiderBernd JaenigenDirk WagnerSiegbert RiegDaniel HornussPaul M BieverWinfried V KernGerd Walz

Published in: PloS one (2021)

Triple therapy is associated with an increase in the incidence of AKI in non-ICU COVID-19 patients. The underlying mechanisms may comprise a CYP3A4 enzyme interaction, and may be relevant for any future therapy combining hydroxychloroquine with antiviral agents.

Keyphrases

sars cov
acute kidney injury
stem cells
risk factors
current status
antiretroviral therapy
bone marrow
replacement therapy